Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antiviral therapy found to prevent blindness, other serious effects for patients with eye shingles

11.03.2003


Mayo Clinic has found that for patients with eye shingles, oral antiviral drugs are critical to prevent long-term consequences in the eye. Untreated, 10 percent of eye shingles patients experience a serious long-term outcome, such as severe visual loss, eyelid scarring or chronic in-turning of the eyelashes; if treated, two percent of patients experience these effects. The Mayo Clinic study refutes the findings of a previous British study of oral antivirals in patients with eye shingles.



"This is the first time it’s been documented that within the eye, the chance of something really bad happening is greatly reduced by administering oral antivirals," says Keith Baratz, M.D., Mayo Clinic ophthalmologist and author of the manuscript, "Herpes Zoster Ophthalmicus in Olmsted County, Minnesota: Have Systemic Antivirals Made a Difference?" to be published in the March issue of Archives of Ophthalmology, http://archopht.ama-assn.org.

This study, based on data from the Rochester Epidemiology Project, http://www.mayo.edu/research/mir/topic_1029.html, is the first long-term follow-up study and the second largest study of this medication with patients diagnosed with herpes zoster opthalmicus. The largest study completed of oral antivirals for this disease to date, by Moorfield’s Eye Hospital in London, found that oral antivirals did not significantly affect long-term outcome; the study was not well controlled, however, according to the Mayo Clinic researchers. Oral antiviral treatment has been controversial due to the Moorfield’s study as well as the cost of the medicine, which can cost several hundred dollars for a course of treatment, or approximately $13 to $22 per day.


This study compared 323 cases of eye shingles treated in Olmsted County, Minn., between 1976 and 1998. Of these cases, two-thirds, or 202 patients, were treated with oral antiviral medication, such as acyclovir, famciclovir or valacyclovir; and one-third, or 121, were not treated. In untreated patients, 8.9 percent experienced adverse outcomes five to 10 years following the onset of the illness; 2.1 percent of treated patients experienced such outcomes. Also, the group given oral antivirals was less likely to experience the complication neurotrophic keratitis, or loss of feeling in and inflammation of the cornea. Those treated, however, did experience more frequent conjunctivitis, or inflammation of the eyelid-lining membrane and sclera surface, for reasons unknown to the investigators.

Timing of treatment also affected the long-term outcome. Those who experienced long-term negative outcomes such as glaucoma, scleritis (inflammation of the white coating around the eyeball), uveitis (inflammation of the vascular middle coating of the eye), corneal edema or stromal keratitis had waited an average of 4.8 days before receiving treatment; those who did not experience these outcomes waited an average of 3.8 days prior to treatment.

"A delay in treatment with the drug negatively affected the course of the disease," says Dr. Baratz. "Getting in to your doctor quickly is an issue."

According to Dr. Baratz, receiving timely treatment for eye shingles is complicated, however, by nonspecific symptoms at the start of the disease. The origin of these early symptoms also is difficult to pinpoint.

"You can get headaches first, or a rash first or pinkeye first," says Dr. Baratz. "Very early on it can be difficult to diagnose." He adds, however, that herpes zoster ophthalmicus is very easy to diagnose once the rash starts.

Herpes zoster, or shingles, is a common condition; 20 percent of all those who have had chicken pox will get shingles, and 20 percent of those experience the disease in the eye. People at higher risk for the disease include the elderly, patients taking immunosuppressant drugs or those experiencing high stress. It may strike people of any age. The virus causing the disease, varicella zoster, can remain in the body and lie "dormant," reactivating years later in nerve cells. Factors such as stress, medications, illness and aging may prompt the reactivation.

"You can get chicken pox when you’re three years old, and it can come back when you’re 70," says Dr. Baratz. " Everyone who has shingles has had chicken pox before. Chicken pox usually is not a big deal; shingles is a big deal."

Herpes zoster most commonly occurs in the body’s trunk, but it also may spread along the ophthalmic portion of the fifth cranial nerve, affecting the eye. The symptoms manifest in one eye only, as shingles typically concentrate on one side of the body.

"It is very painful and can destroy your sight," says Dr. Baratz.

Lisa Copeland | EurekAlert!
Further information:
http://www.mayo.edu/research/mir/topic_1029.html

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>